The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Open accessAbstract
BACKGROUND: In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of secukinumab, an anti-interleukin-17A monoclonal antibody, in such patients. METHODS: In this double-blind, phase 3 study, 606 patients with psoriatic arthritis were randomly assigned in a 1:1:1 ratio to receive intravenous secukinumab (at a dose of 10 mg per kilogram) at weeks 0, 2, and 4, followed by subcutaneous secukinumab at a dose of either 150 mg or 75 mg every 4 weeks, or placebo. Patients in the placebo group were switched to subcutaneous secukinumab at a dose of 150 mg or 75 mg at week 16 or 24, depending on clinical response. The primary end point was the proportion of patients with an American College of Rheumatology 20 (ACR20) response at week 24, defined as a 20% improvement from baseline in the number of tender and swollen joints and at least three other important domains. RESULTS: ACR20 response rates at week 24 were significantly higher in the group receiving secukinumab at doses of 150 mg (50.0%) and 75 mg (50.5%) than in those receiving placebo (17.3%) (P<0.001 for both comparisons with placebo). Secondary end points, including the ACR50 response and joint structural damage, were significantly better in the secukinumab groups than in the placebo group. Improvements were sustained through 52 weeks. Infections, including candida, were more common in the secukinumab groups. Throughout the study (mean secukinumab exposure, 438.5 days; mean placebo exposure, 128.5 days), four patients in the secukinumab groups had a stroke (0.6 per 100 patient-years; 95% confidence interval [CI], 0.2 to 1.5), and two had a myocardial infarction (0.3 per 100 patient-years; 95% CI, 0.0 to 1.0), as compared with no patients in the placebo group. CONCLUSIONS: Secukinumab was more effective than placebo in patients with psoriatic arthritis, which validates interleukin-17A as a therapeutic target. Infections were more common in the secukinumab groups than in the placebo group. The study was neither large enough nor long enough to evaluate uncommon serious adverse events or the risks associated with long-term use. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT01392326.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,382
Taylor, W., Gladman, D., Helliwell, P., Marchesoni, A., Mease, P., & Mielants, H. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21972 · Cited by 3,746
Self-citationAmerican college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Psoriatic arthritis: epidemiology, clinical features, course, and outcome
Gladman, D. D., Antoni, C., Mease, P., Clegg, D. O., & Nash, P. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.032482 · Cited by 1,536
Self-citationInterleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906
Wells, G., Becker, J.-C., Teng, J., Dougados, M., Schiff, M., Smolen, J., Aletaha, D., & van Riel, P. L. C. M. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.084459 · Cited by 878
Han, C., Robinson, D., Hackett, M., Paramore, L. C., Fraeman, K. H., & BALA, M. M. (2006) · PubMed · Cited by 721
Lubberts, E., Koenders, M. I., Oppers‐Walgreen, B., van den Bersselaar, L., Coenen‐de Roo, C. J. J., Joosten, L. A. B., & van den Berg, W. B. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20001 · Cited by 709
Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis
Kagami, S., Rizzo, H. L., Lee, J. J., Koguchi, Y., & Blauvelt, A. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.399 · Cited by 640
Baeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., McInnes, I., van Laar, J. M., Landewé, R., Wordsworth, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61134-4 · Cited by 595
Self-citationGuidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A., Koo, J. Y. M., Lebwohl, M., Leonardi, C. L., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.11.055 · Cited by 460
Gossec, L., Smolen, J. S., Gaujoux-Viala, C., Ash, Z., Marzo-Ortega, H., van der Heijde, D., FitzGerald, O., Aletaha, D., Balint, P., Boumpas, D., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200350 · Cited by 446
Self-citationBrodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Mease, P. J., Genovese, M. C., Greenwald, M. W., Ritchlin, C. T., Beaulieu, A. D., Deodhar, A., Newmark, R., Feng, J., Erondu, N., & Nirula, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315231 · Cited by 395
Self-citationJandus, C., Bioley, G., Rivals, J., Dudler, J., Speiser, D., & Romero, P. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23655 · Cited by 382
McInnes, I. B., Sieper, J., Braun, J., Emery, P., van der Heijde, D., Isaacs, J. D., Dahmen, G., Wollenhaupt, J., Schulze-Koops, H., Kogan, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202646 · Cited by 343
Self-citationCardiovascular morbidity in psoriatic arthritis
Gladman, D. D., Ang, M., Su, L., Tom, B. D. M., Schentag, C. T., & Farewell, V. T. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.094839 · Cited by 304
Menon, B., Gullick, N. J., Walter, G. J., Rajasekhar, M., Garrood, T., Evans, H. G., Taams, L. S., & Kirkham, B. W. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38376 · Cited by 293
Self-citationMease, P. J., & Armstrong, A. W. (2014) · Drugs · doi:10.1007/s40265-014-0191-y · Cited by 271
Self-citationInterleukin‐17–positive mast cells contribute to synovial inflammation in spondylarthritis
Noordenbos, T., Yeremenko, N., Gofita, I., van de Sande, M., Tak, P. P., Caňete, J. D., & Baeten, D. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33396 · Cited by 270
Husted, J. A., Thavaneswaran, A., Chandran, V., Eder, L., Rosen, C. F., Cook, R. J., & Gladman, D. D. (2011) · Arthritis Care & Research · doi:10.1002/acr.20627 · Cited by 264
Bush, K. A., Farmer, K. M., Walker, J. S., & Kirkham, B. W. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10173 · Cited by 252
Self-citationGlintborg, B., Østergaard, M., Krogh, N. S., Andersen, M. D., Tarp, U., Loft, A. G., Lindegaard, H. M., Holland‐Fischer, M., Nordin, H., Jensen, D. V., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37876 · Cited by 202
Saad, A. A., Ashcroft, D. M., Watson, K. D., Hyrich, K. L., Noyce, P. R., Symmons, D. P., & the British Society for Rheumatology Biologics Register (2009) · Arthritis Research & Therapy · doi:10.1186/ar2670 · Cited by 201
Krieg, P., Rosenberger, S. F., de Juanes, S., Latzko, S., Hou, J. L., Dick, A., Kloz, U., van der Hoeven, F., Haußer, I., Esposito, I., et al. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.250 · Cited by 143
Burden of Disease: Psoriasis and Psoriatic Arthritis
Boehncke, W., & Menter, A. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0032-x · Cited by 136
Th17 Cells, Not IL-17+ γδ T Cells, Drive Arthritic Bone Destruction in Mice and Humans
Pöllinger, B., Junt, T., Metzler, B., Walker, U. A., Tyndall, A., Allard, C., Bay, S., Keller, R. P., Raulf, F., Padova, F. D., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003370 · Cited by 131
Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis
Weisman, S. M., Pollack, C., & Gottschalk, R. (2003) · Journal of Dermatological Treatment · doi:10.1080/09546630310013360 · Cited by 82
Klein, U., Liang, E. C. Z., Vogel, B., Kolbinger, F., Bruin, G. J. M., & Lloyd, P. M. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-eular.1868 · Cited by 10
Cited by
Targeting inflammation in atherosclerosis — from experimental insights to the clinic
Soehnlein, O., & Libby, P. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00198-1 · Cited by 1,019
IL-17 and IL-17-producing cells in protection versus pathology
Mills, K. H. G. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00746-9 · Cited by 1,000
Psoriasis pathogenesis and the development of novel targeted immune therapies
Hawkes, J. E., Chan, T. C., & Krueger, J. G. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.004 · Cited by 972
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Blauvelt, A., & Chiricozzi, A. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-018-8702-3 · Cited by 789
Coates, L. C., Soriano, E. R., Corp, N., Bertheussen, H., Callis Duffin, K., Campanholo, C. B., Chau, J., Eder, L., Fernández-Ávila, D. G., FitzGerald, O., et al. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00798-0 · Cited by 627
Self-citation
Metadata
- Authors
- Mease, P. J., McInnes, I. B., Kirkham, B., Kavanaugh, A., Rahman, P., van der Heijde, D., Landewé, R., Nash, P., Pricop, L., Yuan, J., Richards, H. B., & Mpofu, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-10
- Volume
- 373
- Issue
- 14
- Pages
- 1329-1339
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1935617463
- Cited by
- 746
- References
- 32
- FWCI
- 68.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.